Degarelix is a synthetic peptide developed to bind to gonadotropin-releasing hormone (GnRH) receptors in the pituitary. What it also does is block the interaction with GnRH, and this antagonism reduces the luteinizing hormone (LH) as well as the follicle stimulating hormone (FSH), which eventually leads to testosterone suppression.
This peptide is important for treating men with advanced stages of prostate cancer and it was FDA approved way back in 2008.